Abstract
The ATHENA clinical trial enrolled 4,628 patients in 37 countries and evaluated the efficacy of dronedarone 400 mg twice daily versus placebo for the prevention of cardiovascular hospitalisation or death from any cause in patients with paroxysmal or persistent atrial fibrillation or atrial flutter. The trial showed a statistically significant 24% reduction in the primary endpoint cardiovascular hospitalisations or all-cause death. In the current paper, parameters that drive the cost-effectiveness of dronedarone on top of standard therapy versus likely comparators, i.e. amiodarone, sotalol and flecainide, were investigated by means of a health economic model based on the ATHENA clinical trial. Dronedarone is cost-effective, and ICERs are low versus amiodarone with €5,340; €4,620; €3,850 and €5,630 per QALY gained for Canada, Italy, Sweden and Switzerland, respectively. The most significant driving factor for the cost-effectiveness of dronedarone is the increased survival rate for patients on dronedarone.
References
Jul 6, 2000·Journal of Psychosomatic Research·N Frasure-SmithM G Bourassa
Feb 8, 2003·Stroke; a Journal of Cerebral Circulation·Josephine TengSusan Scott
Jul 9, 2004·Circulation·Fayez BokhariPaul Dorian
Dec 14, 2006·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Peter LindgrenUNKNOWN ASCOT investigators
Oct 24, 2007·Brain Research·Eric M MintzJames L Blank
Dec 7, 2007·Bone·Ingrid LekanderJohn A Kanis
Mar 11, 2008·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Anna RingborgHarry J G M Crijns
Apr 9, 2008·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Peter LindgrenBengt Jönsson
Dec 17, 2008·British Journal of Clinical Pharmacology·Andrew J B WallW S Waring
Dec 26, 2008·European Heart Journal·Masoud ShafazandAnnika Rosengren
Feb 14, 2009·The New England Journal of Medicine·Stefan H HohnloserUNKNOWN ATHENA Investigators
Feb 24, 2009·Lancet Neurology·Valery L FeiginVarsha Parag
Aug 14, 2009·Journal of Travel Medicine·Poh Lian LimEng Eong Ooi
Sep 16, 2009·Circulation·Stuart J ConnollyUNKNOWN ATHENA Investigators
Oct 3, 2009·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Yasuni NakanumaAzusa Kiktao
Jan 29, 2010·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Jenny BergHarry Crijns
Apr 14, 2010·Journal of Cardiovascular Electrophysiology·Jean-Yves Le HeuzeyJean-Marc Davy
Jul 2, 2010·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Lisa EricsonIngela Björholt
Jan 14, 2011·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Nick FreemantleMatthew Reynolds
Nov 16, 2011·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN PALLAS Investigators
Jul 10, 2012·Clinical Therapeutics·Örjan ÅkerborgMatthew Reynolds
Citations
Apr 30, 2013·The Canadian Journal of Cardiology·Jenny BergPeter Lindgren
Mar 7, 2018·Expert Opinion on Emerging Drugs·Alessandro CapucciIrene Giannini
Jun 26, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Sigrid PieningPeter G M Mol
Jun 3, 2014·BMC Public Health·Pauline Zardo, Alex Collie